Filing Flows › Companies › Sarepta Therapeutics › Timeline
Sarepta Therapeutics stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions+1.0% to $17.82
Sarepta Therapeutics (SRPT) stock rose 1% over the last 252 sessions, to $17.82. On the way it reported 4 quarters, its insiders filed 2 open-market trades, and the company filed 6 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 5, 2026 | Earnings | Earnings: missed the EPS estimate by -63.6% | −7.8% (−3.3% vs SPY) | — | — |
| Sep 23, 2026 | 8-K | Material definitive agreement | −3.0% (−2.9% vs SPY) | −3.9% (−3.3% vs SPY) | −4.1% (−3.6% vs SPY) |
| Aug 5, 2026 | Earnings | Earnings: beat the EPS estimate by 31.7% | −2.8% (−2.7% vs SPY) | +10.6% (+10.7% vs SPY) | +34.8% (+35.6% vs SPY) |
| Jul 27, 2026 | 8-K | Directors and officers: departures, appointments, pay | +1.3% (+1.3% vs SPY) | −5.4% (−6.5% vs SPY) | +14.5% (+11.2% vs SPY) |
| Jun 4, 2026 | 8-K | Directors and officers: departures, appointments, pay | −5.6% (−3.0% vs SPY) | −10.5% (−7.9% vs SPY) | +17.2% (+18.2% vs SPY) |
| May 6, 2026 | Earnings | Earnings: beat the EPS estimate by 202.1% | +5.5% (+4.2% vs SPY) | −13.0% (−15.0% vs SPY) | −26.9% (−31.4% vs SPY) |
| Mar 12, 2026 | Insider sale | Mayo Stephen sold $123K | −3.1% (−1.6% vs SPY) | −2.4% (−0.2% vs SPY) | +18.6% (+17.9% vs SPY) |
| Feb 25, 2026 | 8-K | Directors and officers: departures, appointments, pay | −8.4% (−7.8% vs SPY) | −16.5% (−15.3% vs SPY) | +13.4% (+20.3% vs SPY) |
| Feb 25, 2026 | Earnings | Earnings: missed the EPS estimate by -365.3% | +0.7% (−0.1% vs SPY) | −17.1% (−16.1% vs SPY) | +23.2% (+27.5% vs SPY) |
| Dec 19, 2025 | 8-K | Material definitive agreement | +0.9% (+0.3% vs SPY) | +3.6% (+2.6% vs SPY) | +3.5% (+2.3% vs SPY) |
| Dec 16, 2025 | Insider sale | Estepan Ian Michael sold $294K | +3.5% (+3.7% vs SPY) | −1.5% (−2.4% vs SPY) | −1.1% (−3.1% vs SPY) |
| Dec 8, 2025 | 8-K | Directors and officers: departures, appointments, pay | −1.8% (−1.5% vs SPY) | −3.3% (−2.7% vs SPY) | +5.2% (+4.4% vs SPY) |
Insiders’ record here
In the year on the chart, Sarepta Therapeutics' insiders reported 0 open-market buys ($0) and 2 sales ($417K). Of the 2 old enough to score, 2 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was — and after a sale −22.6%.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
| 2.03 New debt or off-balance-sheet obligation | 13,268 | 0.0% | 50% | +1.2% | ±1.3% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Sarepta Therapeutics: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.